NEJM: Nubeqa (darolutamide) significantly extends the lifespan of patients with non-metastatic prostate cancer!

The ARAMIS study showed the total lifetime of male patients receiving Nubeqa (darolutamide) combined with ADT for non-metastatic destastic prostate cancer (nmCRPC) compared to placebo combined androgen deprivation therapy (ADT) (OS) has improved significantly (HR s 0.69, 95% CI 0.53-0.88, p s 0.003), and all other secondary endpoints have improved significantly.
, the rate of adverse events is consistent with the use of ADTs alone.
results were published recently in the New England Journal of Medicine, NEJM.
Karim Fizazi, head of research at ARAMIS, said: "Through ongoing research, we have identified treatments that focus on extending life expectancy and reducing side effects in men with nmCRPC."
men who received drarolutamide combined androgen deprivation therapy (ADT) showed significant improvement in OS compared to placebo combined ADT, and a 31% lower risk of death (HR s 0.69, 95% CI 0.53-0.88, p s 0.003).
Although more than half (56%) of patients in the placebo group (309 out of 554 patients) received follow-up drarolutamide or other life-extending treatments at the end of the data analysis period (15 November 2019), OS benefits were observed.
.